189 related articles for article (PubMed ID: 19817936)
1. Cost-effectiveness of treating resistant hypertension with an implantable carotid body stimulator.
Young KC; Teeters JC; Benesch CG; Bisognano JD; Illig KA
J Clin Hypertens (Greenwich); 2009 Oct; 11(10):555-63. PubMed ID: 19817936
[TBL] [Abstract][Full Text] [Related]
2. What price for blood pressure control?
Textor SC
J Clin Hypertens (Greenwich); 2009 Oct; 11(10):537-9. PubMed ID: 19817933
[No Abstract] [Full Text] [Related]
3. Applicability and cost-effectiveness of the Systolic Blood Pressure Intervention Trial (SPRINT) in the Chinese population: A cost-effectiveness modeling study.
Li C; Chen K; Cornelius V; Tomeny E; Wang Y; Yang X; Yuan X; Qin R; Yu D; Wu Z; Wang D; Chen T
PLoS Med; 2021 Mar; 18(3):e1003515. PubMed ID: 33661907
[TBL] [Abstract][Full Text] [Related]
4. InnovaSEC in Action: Cost-effectiveness of Barostim in the Treatment of Refractory Hypertension in Spain.
Soto M; Sampietro-Colom L; Sagarra J; Brugada-Terradellas J
Rev Esp Cardiol (Engl Ed); 2016 Jun; 69(6):563-71. PubMed ID: 26907729
[TBL] [Abstract][Full Text] [Related]
5. The Cost-Effectiveness of Low-Cost Essential Antihypertensive Medicines for Hypertension Control in China: A Modelling Study.
Gu D; He J; Coxson PG; Rasmussen PW; Huang C; Thanataveerat A; Tzong KY; Xiong J; Wang M; Zhao D; Goldman L; Moran AE
PLoS Med; 2015 Aug; 12(8):e1001860. PubMed ID: 26241895
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of Barostim therapy for the treatment of resistant hypertension in European settings.
Borisenko O; Beige J; Lovett EG; Hoppe UC; Bjessmo S
J Hypertens; 2014 Mar; 32(3):681-92. PubMed ID: 24378998
[TBL] [Abstract][Full Text] [Related]
7. An implantable carotid sinus stimulator for drug-resistant hypertension: surgical technique and short-term outcome from the multicenter phase II Rheos feasibility trial.
Illig KA; Levy M; Sanchez L; Trachiotis GD; Shanley C; Irwin E; Pertile T; Kieval R; Cody R
J Vasc Surg; 2006 Dec; 44(6):1213-1218. PubMed ID: 17145423
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of Intensive vs Standard Blood Pressure Control Among Older Patients With Hypertension.
Liao CT; Toh HS; Sun L; Yang CT; Hu A; Wei D; Melgarejo J; Zhang ZY
JAMA Netw Open; 2023 Feb; 6(2):e230708. PubMed ID: 36848091
[TBL] [Abstract][Full Text] [Related]
9. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients.
Heusser K; Tank J; Engeli S; Diedrich A; Menne J; Eckert S; Peters T; Sweep FC; Haller H; Pichlmaier AM; Luft FC; Jordan J
Hypertension; 2010 Mar; 55(3):619-26. PubMed ID: 20101001
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of Intensive Blood Pressure Management.
Richman IB; Fairley M; Jørgensen ME; Schuler A; Owens DK; Goldhaber-Fiebert JD
JAMA Cardiol; 2016 Nov; 1(8):872-879. PubMed ID: 27627731
[TBL] [Abstract][Full Text] [Related]
11. Telemonitoring and self-management in the control of hypertension (TASMINH2): a cost-effectiveness analysis.
Kaambwa B; Bryan S; Jowett S; Mant J; Bray EP; Hobbs FD; Holder R; Jones MI; Little P; Williams B; McManus RJ
Eur J Prev Cardiol; 2014 Dec; 21(12):1517-30. PubMed ID: 23990660
[TBL] [Abstract][Full Text] [Related]
12. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study.
Scheffers IJ; Kroon AA; Schmidli J; Jordan J; Tordoir JJ; Mohaupt MG; Luft FC; Haller H; Menne J; Engeli S; Ceral J; Eckert S; Erglis A; Narkiewicz K; Philipp T; de Leeuw PW
J Am Coll Cardiol; 2010 Oct; 56(15):1254-8. PubMed ID: 20883933
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension.
Geisler BP; Egan BM; Cohen JT; Garner AM; Akehurst RL; Esler MD; Pietzsch JB
J Am Coll Cardiol; 2012 Oct; 60(14):1271-7. PubMed ID: 22981547
[TBL] [Abstract][Full Text] [Related]
14. Implantable carotid sinus stimulator for the treatment of resistant hypertension: local effects on carotid artery morphology.
Sanchez LA; Illig K; Levy M; Trachiotis G; Shanley C; Irwin E; Jim J; Rossing M; Kieval R
Ann Vasc Surg; 2010 Feb; 24(2):178-84. PubMed ID: 20036504
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of primary prevention of cardiovascular diseases in mild hypertension: a scenario analysis for the Netherlands.
Stevanović J; O'Prinsen AC; Verheggen BG; Schuiling-Veninga N; Postma MJ; Pechlivanoglou P
Clin Ther; 2014 Mar; 36(3):368-84.e5. PubMed ID: 24534654
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of screening and optimal management for diabetes, hypertension, and chronic kidney disease: a modeled analysis.
Howard K; White S; Salkeld G; McDonald S; Craig JC; Chadban S; Cass A
Value Health; 2010; 13(2):196-208. PubMed ID: 19878493
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of renin-guided treatment of hypertension.
Smith SM; Campbell JD
Am J Hypertens; 2013 Nov; 26(11):1303-10. PubMed ID: 24048147
[TBL] [Abstract][Full Text] [Related]
18. Renal responses to long-term carotid baroreflex activation therapy in patients with drug-resistant hypertension.
Alnima T; de Leeuw PW; Tan FE; Kroon AA;
Hypertension; 2013 Jun; 61(6):1334-9. PubMed ID: 23589562
[TBL] [Abstract][Full Text] [Related]
19. Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin: systematic review and economic evaluation.
Simpson EL; Duenas A; Holmes MW; Papaioannou D; Chilcott J
Health Technol Assess; 2009 Mar; 13(17):iii, ix-x, 1-154. PubMed ID: 19331797
[TBL] [Abstract][Full Text] [Related]
20. An early analysis of cost-utility of baroreflex activation therapy in advanced chronic heart failure in Germany.
Borisenko O; Müller-Ehmsen J; Lindenfeld J; Rafflenbeul E; Hamm C
BMC Cardiovasc Disord; 2018 Aug; 18(1):163. PubMed ID: 30092774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
